報價延遲最少15分鐘:2026/11/14 14:16 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.17 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.36/0.44
|
|
企業價值
47.65B
|
| 資產負債 |
|
每股賬面淨值
5.02
|
| 現金流量 |
|
現金流量率
0.09
|
| 損益表 |
|
收益
11.03B
|
|
每股收益
3.28
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of salesfrom global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition. |
